Records
Browse every document routed through Assort Design.
Route Filters
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor January 9, 2026 PDF Version Agreement expands Madrigal’s pipeline and stre
One-line summary: Madrigal Pharmaceuticals expands its MASH pipeline through an exclusive global license for ervogastat, a Phase 2 oral DGAT-2 inhibitor, complementing its approved therapy Rezdiffra for innovative combination MASH treatments.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited July 30, 2025 PDF Version License agreement supports M
One-line summary: Madrigal Pharmaceuticals licenses orally-administered GLP-1 agonist SYH2086 to develop a best-in-class combination therapy with Rezdiffra for MASH treatment.
Citations: 5 · Risk: 1 High / 2 Medium / 0 Low